PRIME MINISTER Boris Johnson will address lawmakers on Tuesday (7) on his plans to fix Britain's social care system, with many in his own party furious that he wants to pay for it by hiking taxes in a clear breach of his election pledges.
After splurging on the Covid-19 pandemic, Johnson is now trying to address Britain's creaking social care system, whose costs are projected to double as the population ages over the next two decades.
For years, British politicians have been trying to find a way to pay for social care, though successive Labour and Conservative prime ministers have ducked the issue because they feared it would anger voters and their own parties.
Johnson wants to raise the National Insurance (NI) tax paid by around 25 million working people to subsidise care for pensioners, including wealthy retirees, according to British media.
The prime minister will chair a cabinet meeting on Tuesday (7) morning and is afterwards expected to address parliament at around 1130 GMT. Johnson, his finance secretary Rishi Sunak and health minister Sajid Javid will then hold a news conference.
"We must act now to ensure the health and care system has the long-term funding it needs to continue fighting Covid and start tackling the backlogs, and end the injustice of catastrophic costs for social care," Johnson will tell parliament, according to extracts released by his office.
"My government will not duck the tough decisions needed to get NHS (National Health Service) patients the treatment they need and to fix our broken social care system."
Like many other Western leaders, Johnson is facing demands to spend more on welfare even though government borrowing has ballooned to 14.2 per cent of economic output - a level last seen at the end of World War Two.
For Johnson, who helped win the 2016 Brexit vote and then as prime minister presided over Britain's exit from the EU, fixing social care "once and for all" offers a possible way to broaden his domestic legacy.
In 2019, Johnson said he had a plan for social care and promised to prevent the elderly having to sell their houses to pay for care.
But his plan is a gamble.
Though Johnson won the biggest Conservative majority since Margaret Thatcher, many of the party's lawmakers worry his government lacks both a big-picture reform plan for the United Kingdom and the talent to implement one.
TAX RISE
Although the next national election is not due until 2024, many Conservatives say that raising taxes will hurt their positioning as the party of low taxation.
"A tax rise suggests ministers are increasingly conscious that the country cannot live on fantasy money. That, at least, is to be welcomed," said William Hague, a former Conservative Party leader.
"The reality of reduced take home pay to deal with a problem out of sight of most people will be unwelcome when it bites," Hague said, adding that fringe parties would benefit from the tax rise.
Johnson's office and the finance ministry have repeatedly refused to detail financing plans, but British media have reported that the prime minister wants to raise NI, paid by working people and employers.
Many Conservative lawmakers worry this will hurt younger, low-income workers and breach his 2019 election guarantee not to raise the tax.
The alternatives to raising national insurance are increasing income tax or imposing a wealth tax of some kind.
Under the current care system, anyone with assets over £23,350 ($32,305) pays for their care in full. This can lead to spiralling costs and the complete liquidation of someone's assets.
The Telegraph newspaper said lawmakers could face a snap vote on the social care plans later this week.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.